Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-18

FDA Approved: ZOLMIPTRIPTAN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

The FDA approved Glenmark's supplemental application for Zolmitriptan (ZOLMIPTRIPTAN) under ANDA 202560. This represents a supplemental approval for an existing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zolmitriptan (zolmitriptan)

Snippet

SUPPL AP for ZOLMIPTRIPTAN (ZOLMITRIPTAN)